Skip to main content

Table 3 Summary statistics of FOI phases 1-3 and PMV at baseline, w6, w12, w24 and w52

From: Monitoring of patients with rheumatoid arthritis by indocyanine green (ICG)-enhanced fluorescence optical imaging treated with anti-TNFα therapy

  N Median (min-max, IQR) p-value
Phase 1
 Baseline 28 1.5 (0–16, 9.25)  
 w6 27 1.0 (0–12, 3.00) 0.069
 w12 28 0.5 (0–46, 3.00) 0.171
 w24 27 0.0 (0–10, 3.00) 0.004
 w52 18 0.0 (0–13, 1.75) 0.091
Phase 2
 Baseline 28 19.5 (0–36, 14.50)  
 w6 27 19.0 (0–43, 13.50) 0.451
 w12 28 19.0 (0–50, 13.25) 0.071
 w24 27 15.0 (1–48, 15.50) 0.310
 w52 18 19.0 (0–35, 12–75) 0.256
Phase 3
 Baseline 28 1.0 (0–20, 3.75)  
 w6 27 2.0 (0.22, 3.50) 0.501
 w12 28 2.5 (0–32, 6.25) 0.089
 w24 27 1.0 (0–17, 3.00) 0.191
 w52 18 0.5 (0–12, 2.00) 0.959
PMV
 Baseline 28 5.0 (0–27, 7.00)  
 w6 27 8.0 (0–25, 7.00) 0.018
 w12 28 5.5 (0–36, 9.25) 0.472
 w24 27 7.0 (0–23, 8.50) 0.204
 w52 18 5.5 (0–23, 5.75) 0.717
  1. FOI fluorescence optical imaging, PMV PrimaVistaMode, IQR interquartile range; significance level of p < 0.05
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us